In the future, patients with advanced breast cancer with BRCA1/2 mutation in China and the United States will be more inclined to choose talazoparib as the first choice of treatment, rather than the traditional Eribulin, capecitabine, gemcitabine, and vinorelbine treatment. Here, BRCA1 is linked to breast cancer.